Phase 1 Study of CS-7017 - Evaluation of Safety and Pharmacokinetics of CS-7017 in Japanese Patients With Solid Cancer

DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 12 人开始时间: 2009年12月11日最近更新: 2023年10月17日

试验速览

暂无简介。

•Histologically or cytologically diagnosed metastatic solid cancers which are not curable with, or not eligible for standard treatment(s)
•-ECOG performance status: 0-1

•-History of any of the following events within 6 months prior to start of study treatment myocardial infraction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or cerebral infraction, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolic event, clinically significant pulmonary disease (eg severe COPD or asthma)
•-Patient with a clinically active brain metastasis, or who need drugs to control adverse event like edema and pleural effusion
•-Inflammatory bowel disease, or partial bowel obstruction
•-Patients with any severe or uncontrolled intercurent diseases

发起方

DAIICHISANKYO Co.,Ltd.